Martingale Asset Management L P increased its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 75.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,783 shares of the company's stock after buying an additional 14,946 shares during the period. Martingale Asset Management L P owned 0.06% of Harmony Biosciences worth $1,391,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of HRMY. Price T Rowe Associates Inc. MD boosted its holdings in shares of Harmony Biosciences by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,219 shares of the company's stock valued at $478,000 after buying an additional 1,201 shares during the period. SG Americas Securities LLC acquired a new stake in Harmony Biosciences in the second quarter valued at $138,000. Hennion & Walsh Asset Management Inc. lifted its stake in Harmony Biosciences by 214.1% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 44,945 shares of the company's stock valued at $1,356,000 after acquiring an additional 30,638 shares during the last quarter. Summit Global Investments lifted its stake in Harmony Biosciences by 4.2% in the second quarter. Summit Global Investments now owns 20,164 shares of the company's stock valued at $608,000 after acquiring an additional 807 shares during the last quarter. Finally, nVerses Capital LLC acquired a new stake in Harmony Biosciences in the second quarter valued at $36,000. Institutional investors own 86.23% of the company's stock.
Insider Buying and Selling at Harmony Biosciences
In other news, insider Jeffrey Dierks sold 21,496 shares of the firm's stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $40.47, for a total value of $869,943.12. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 30.80% of the company's stock.
Harmony Biosciences Price Performance
HRMY stock traded up $0.46 during mid-day trading on Monday, hitting $35.13. The stock had a trading volume of 600,916 shares, compared to its average volume of 476,611. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. Harmony Biosciences Holdings, Inc. has a 52 week low of $28.14 and a 52 week high of $41.61. The firm has a market capitalization of $2.00 billion, a P/E ratio of 16.65, a P/E/G ratio of 0.64 and a beta of 0.77. The firm has a fifty day simple moving average of $35.09 and a 200 day simple moving average of $33.79.
Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last released its earnings results on Tuesday, October 29th. The company reported $0.79 EPS for the quarter, beating the consensus estimate of $0.64 by $0.15. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm had revenue of $186.00 million for the quarter, compared to analyst estimates of $184.07 million. During the same period last year, the firm earned $0.63 EPS. The business's quarterly revenue was up 16.0% compared to the same quarter last year. As a group, research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.36 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of analysts have commented on HRMY shares. Needham & Company LLC reiterated a "buy" rating and issued a $52.00 price target on shares of Harmony Biosciences in a research note on Tuesday, October 29th. Mizuho increased their price objective on shares of Harmony Biosciences from $42.00 to $52.00 and gave the company an "outperform" rating in a research report on Thursday, October 10th. Cantor Fitzgerald increased their price objective on shares of Harmony Biosciences from $51.00 to $58.00 and gave the company an "overweight" rating in a research report on Wednesday, October 30th. Raymond James reissued an "outperform" rating and issued a $40.00 price objective on shares of Harmony Biosciences in a research report on Thursday, October 10th. Finally, UBS Group started coverage on shares of Harmony Biosciences in a research report on Tuesday, September 10th. They issued a "buy" rating and a $56.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $47.00.
Check Out Our Latest Stock Analysis on Harmony Biosciences
Harmony Biosciences Profile
(
Free Report)
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Further Reading
Before you consider Harmony Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.
While Harmony Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
